Here, microneedle patches containing dextran NPs loaded with anti-PD-1 antibodies and glucose oxidase were used to deliver checkpoint inhibitors to melanoma in a pH-dependent manner (Wang et al., 2016; Han et al., 2020). Here, PDCD1 is linked to melanoma.